Update on systemic treatment in early triple negative breast cancer

被引：29

作者：

Nunez Abad, Martin ^{[1
]}

Calabuig-Farinas, Silvia ^{[2
,4
,5
,6
,7
]}

Lobo de Mena, Miriam ^{[1
]}

Sanz de Bremond, Maria Jose Godes ^{[1
]}

Garcia Gonzalez, Clara ^{[1
]}

Torres Martinez, Susana ^{[2
,4
]}

Angel Garcia-Garcia, Jose ^{[8
]}

Iranzo Gonzalez-Cruz, Vega ^{[1
,2
,3
]}

Camps Herrero, Carlos ^{[1
,2
,4
,6
,7
]}

机构：

[1] Univ Gen Hosp Valencia, Dept Med Oncol, Tres Cruces 2, Valencia 46014, Spain

[2] CIBERONC, Madrid, Spain

[3] Univ Valencia, Dept Med, Valencia, Spain

[4] Univ Gen Hosp Valencia, Gen Univ Hosp Res Fdn, Mol Oncol Lab, Valencia, Spain

[5] Univ Valencia, Dept Pathol, Valencia, Spain

[6] Principe Felipe Res Ctr, Mixed Unit TRIAL, Valencia, Spain

[7] Gen Univ Hosp Valencia Res Fdn, Valencia, Spain

[8] Univ Gen Hosp Valencia, Dept Pathol Anat, Valencia, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷

关键词：

chemotherapy; immunotherapy; neoadjuvant therapy; precision medicine; systemic treatment; triple negative breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; STANDARD NEOADJUVANT CHEMOTHERAPY; SURGICAL ADJUVANT BREAST; PHASE-III TRIAL; OPEN-LABEL; PREOPERATIVE DOXORUBICIN; ANDROGEN RECEPTOR; PROGNOSTIC VALUE; PACLITAXEL; CYCLOPHOSPHAMIDE;

D O I：

10.1177/1758835920986749

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.

引用

页数：18

共 50 条

[1] Optimal Systemic Treatment for Early Triple-Negative Breast Cancer
Furlanetto, Jenny
Loibl, Sibylle
BREAST CARE, 2020, 15 (03) : 217 - 226
[2] Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
Priyanka Sharma
Current Treatment Options in Oncology, 2018, 19
[3] Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
Sharma, Priyanka
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (05)
[4] Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update
Brown, Lauren C.
Loi, Sherene
BREAST, 2022, 62 : S29 - S33
[5] Systemic treatment strategies for triple-negative breast cancer
Yadav, Budhi Singh
Sharma, Suresh C.
Chanana, Priyanka
Jhamb, Swaty
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (02): : 125 - 133
[6] Advances in the systemic treatment of triple-negative breast cancer
Lebert, J. M.
Lester, R.
Powell, E.
Seal, M.
McCarthy, J.
CURRENT ONCOLOGY, 2018, 25 : S142 - S150
[7] Triple-negative breast cancer: an update
Boolbol, Susan K.
Cate, Sarah P.
BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
[8] Treatment options in early triple-negative breast cancer Update from the San Antonio Breast Cancer Symposium 2019
Suppan, Christoph
Balic, Marija
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (03) : 346 - 348
[9] Advances in the Treatment of Triple-negative Early Breast Cancer
Basso, Stefano M. M.
Santeufemia, Davide A.
Fadda, Giovanni M.
Tozzoli, Renato
D'Aurizio, Federica
Lumachi, Franco
MEDICINAL CHEMISTRY, 2016, 12 (03) : 268 - 272
[10] Adjuvant systemic treatment for individual patients with triple negative breast cancer
Oakman, Catherine
Moretti, Erica
Galardi, Francesca
Biagioni, Chiara
Santarpia, Libero
Biganzoli, Laura
Di Leo, Angelo
BREAST, 2011, 20 : S135 - S141

← 1 2 3 4 5 →